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The recently emerged coronavirus pandemic (COVID-19) has become a
worldwide threat affecting millions of people, causing respiratory system
related problems that can end up with extremely serious consequences.
As the infection rate rises significantly and this is followed by a dramatic
increase in mortality, the whole world is struggling to accommodate change
and is trying to adapt to new conditions. While a significant amount of
effort is focused on developing a vaccine in order to make a game-changing
anti-COVID-19 breakthrough, novel coronavirus (SARS-CoV-2) is also devel-
oping mutations rapidly as it transmits just like any other virus and there is
always a substantial chance of the invented antibodies becoming ineffective
as a function of time, thus failing to inhibit virus-to-cell binding efficiency
as the spiked protein keeps evolving. Hence, controlling the transmission of
the virus is crucial. Therefore, this review summarizes the viability of corona-
viruses on inanimate surfaces under different conditions while addressing the
current state of known chemical disinfectants for deactivation of the
coronaviruses. The review attempts to bring together a wide spectrum of
surface–virus–cleaning agent interactions to help identify material selection
for inanimate surfaces that have frequent human contact and cleaning
procedures for effective prevention of COVID-19 transmission.1. Introduction
Having their first examples observed as zoonotic types of viruses back in the
1960s, the term coronavirus covers a broad range of respiratory virus family,
which is responsible for various diseases, showing a variety of symptoms like
mild and common cold while in certain situations severe respiratory syndromes
can also be observed as a consequence of contact with that virus family [1,2].
Before the first significant threat emerged, there was only one type of corona-
virus, called human coronavirus (human-CoV), that was known to infect
humans and display common cold like symptoms as well as acute respiratory
illnesses that would cause more serious problems [3]. Furthermore, until now,
there were two types of coronaviruses which made a noticeable impact by
showing aggressive symptoms on a level of epidemy, namely severe acute
respiratory syndrome (SARS) caused by SARS-CoV back in 2002 and Middle
East respiratory syndrome (MERS) originating from MERS-CoV in 2012
which are both directly linked to betacoronaviruses (β-CoV) that are known
to be able to infect mammalians [4,5]. Coming from the same β-CoV genus,
the most serious and recent variety of coronavirus (COVID-19) has emerged
to cause a worldwide pandemic which was announced by the World Health
Organization (WHO) on 11 March 2020 [6]. As of 20 September 2020, the
weekly epidemiological update announced by theWHO showed that the current




2were fatalmeaning that themortality ratewas around 3.1% [7].
As the infection rate rise over time increases, it has become a
severe threat worldwide on many levels, such as public
health, the global economyand the social wellbeing of individ-
uals. In order to overcome this pandemic and tackle its spread,
requirements for understanding the spreading mechanism
becomes essential. Latest reports have indicated that COVID-
19 spreads through different ways and themost surprising dis-
cussion is made on the rare possibility of transmission via the
digestive tract because of the successful isolation of the virus
from faeces, which gives the situation awhole newperspective
in terms of transmission [8,9]. However, among all rare possi-
bilities, the principal transmission route of the virus is
reported to be through the respiratory tract, using droplets
and excretions originating from the respiratory system,
spreading via coughing and direct contact of those vectors
with the mucous membranes of humans [10]. This is also fol-
lowed by airborne transmission since the smaller droplets tend
to evaporate much faster compared to the bigger ones. There-
fore, the virus continues to travel in the air, which creates a
significant risk of transmission indoors and in crowded
places such as supermarkets, theatres, offices and public trans-
port [11]. Beside the direct contact made with the virus
carrying droplets, there is a substantial risk of indirect contact
with virus-contaminated surfaces that individuals interact on
a daily basis. Nevertheless, the droplet and airborne trans-
mission are reported to be one of the major ways for the
virus to spread and usage of personal protective equipment
is the mainly adopted way to prevent the spread of the
COVID-19, eliminating the presence of the coronavirus from
the surfaces that we interact on a daily basis. This
is something that has to be investigated thoroughly and is
equally important as the current precautions that are taken
to slow down the spread of COVID-19 are frequently revised.
In order to remove the virus from those surfaces,
the healthcare industry has already adopted various types
of disinfectants and biocidal agents such as alcohol, hydro-
gen peroxide and sodium hypochlorite [12]. However, the
importance of a detailed investigation about coronavirus per-
sistence on inanimate surfaces and removal of the virus from
those surfaces is a rather undeniable truth than a topic of
debate! Therefore, this review focuses on surfaces that pose
a risk to became vectors in terms of transmitting coronavirus,
how long the virus can survive on different surfaces and
interaction of the coronavirus and different material types
as well as cleaning agents for optimized removal of the coro-
naviruses. It also elucidates how metallic nanoparticles,
antiviral drugs and nanotechnological approaches can be
used to reduce the transmission rate of infection and prevent
any future outbreaks.2. Transmission of COVID-19
Respiratory droplets, which are bigger than 5–10 µm in diam-
eter and droplet nuclei that are smaller than 5 µm in diameter
are the primary reasons for respiratory infections to be trans-
mitted from one to another [13]. It has been previously
reported that droplets which are bigger than 5 µm are most
likely to be encountered via the upper respiratory tract such
as nose, throat and oropharynx, respectively, while the smal-
ler droplet nuclei can pass through and deposit inside the
lower respiratory system elements such as bronchi and alveoliwhen they are inhaled [14]. It is certain that there is a signifi-
cant risk of being infected by coronavirus after being exposed
to those respiratory droplets and droplet nuclei coming from
an infected person who has respiratory symptoms, especially
when the virus carrying droplets contacts with the mucous
membrane of the mouth, the nose as well as conjunctiva of
eyes [15,16]. Furthermore, there is another direct risk factor
called airborne transmission, where the air becomes a
vector to carry and also hold the droplet nuclei, thus small
particles carrying the virus can be inhaled directly to the
lower respiratory tract. Figure 1 summarizes the transmission
of COVID-19 by schematizing the spread of the droplets
and droplet nuclei after coughing. It has been previously
reported that the virus can survive up to 3 h as droplets in
the air, after being coughed out by the infected person [17].
That kind of a mechanism poses a significant threat for
indoor and crowded environments in both a direct and indir-
ect manner where the droplet nuclei can carry the virus
during an indoor scenario allowing individuals to have
direct contact with the virus [18].
This can be followed by another mechanism of trans-
mission which is more uncertain and elusive as the droplet
nuclei spreads through an ‘unpredictable’ route, travels in
the air up to tens of metres as their liquid content evaporates,
eventually precipitating on the surfaces of indoor elements
such as door handles, handrails, or elsewhere there is frequent
human interaction, thus making inanimate objects vectors of
transmission [19]. Furthermore, β-CoV genus coronaviruses
such as SARS-CoV, MERS-CoV and SARS-CoV-2 are reported
to have heterogeneity in terms of transmissibility, which
defines an extremely aggressive spreading phenomenon
particularly observed in hospital environments [20]. Nowa-
days, various types of personal protective equipment (PPE)
have been widely adopted by hospital staff and individuals
in daily life in order to tackle this aggressive transmission
[21]. Especially, usage of different types of face masks and
making a habit of wearing PPE has successfully provided a
proper way of protection to the wearers against such risks
[22,23]. However, contact routes created by inanimate objects
acting as vectors of transmission after being exposed to the res-
piratory tracts of an infected person still carries a significant
risk in terms of transmission since they are not easy to track.
Therefore, a detailed investigation of the contact routes and
transmission via those contact surfaces plays a key role in con-
trolling the outbreak by better management of the risky
surfaces and regulation of those routes in terms of hygiene.3. Taxonomy, action mechanism and receptor
recognition of coronaviruses
Coming from the Coronaviridae family (figure 2), SARS-CoV-2
is a member of β-CoV genus and reported to be similar to the
SARS-CoV, MERS-CoV and other human coronaviruses in
terms of taxonomy and genetics [24,25]. Therefore, it must
be accurate and beneficial for scientists to take those ‘relatives’
of SARS-CoV-2 into account since there are very limited data
about this newly emerged threat and prevention measures
adopted during previous research and virus outbreaks play
a significant role while developing new strategies against
SARS-CoV-2. Thus, coronaviruses are known to carry posi-
tive-stranded and encapsulated RNA that is meant to be
delivered into the host cells in order to start the infection.
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Cell to virus interactions via proteins on each surface plays a
crucial role in this matter, determining the host range of the
coronaviruses [26]. Moreover, understanding the structure of
the coronaviruses would be helpful in the future for solving
the attachment mechanism to the inanimate surfaces as well.
Responsible for the current pandemic, the SARS-CoV-2
coronavirus carries a different structure of proteins which
are membrane glycoprotein (M), spike protein (S), haemag-
glutinin esterase (HE) and envelope (E) protein as shown in
figure 3a and the nucleocapsid protein (N) can be found
inside the lipid layer, which accompanies the viral RNA
and protects it. Even though the role of those proteins is
not fully understood, recent studies showing that M is the
most frequently detected protein on the virus surface,
which is responsible for the shape of the membrane of the
coronavirus and is also believed to be included in the mech-
anism of the virus to cell binding interactions [27]. On the
contrary, E is found in small quantitates and responsible for
the release of the viral content. It has been previously
reported that ion channel activity on this protein is required
for the development of the disease in terms of pathological
activity [28]. Finally, it would be hard to overstate the impor-
tance of S and HE on the cell binding mechanism of the
coronaviruses. S proteins which are reported to be a class I
fusion protein are responsible for attachment to the host
receptors [29,30]. In a scenario where a coronavirus interacts
with a human cell, identification of the cell is made via the
enzymes on it. After the S protein of the SARS-CoV-2 is
primed by the TMPRSS2 enzyme on the cell wall, engage-
ment on the attachment receptor angiotensin-converting
enzyme 2 (ACE2) of the cell is made by S proteins of the cor-
onavirus in order to initiate the entrance procedure on the
inside of the host cell (figure 3b) [31]. As another important
aspect in cell entry mechanism, HE protein is also believed
to play a key role to enhance and support the functions ofS as well as in allowing the virus to transmit through the
mucosal tissue [32].4. Persistence of the coronaviruses on different
surfaces
As one of themost important concepts in indirect transmission
of the COVID-19, material type of the surfaces plays an
important role since elements of inanimate environment
could act as fomites (inanimate objects which can carry
microbes, acting as vectors that can help spread of the viruses),
allowing the virus to remain viable over a long timescale [33].
Healthy individuals contacting contaminated surfaces as part
of their daily routine allow transmission to happen from an
infected to a healthy person even though there is no direct con-
tact. Hence, this elusiveness forces medical personnel and
scientists to take serious precautions and reconsider the
material selection on the most popular elements of door
handles, handrails, or elevator buttons. In addition, research-
ers have reported studies evaluating the substantiality of
different types of coronaviruses with different inoculums on
different surfaces.
For the SARS coronavirus, Duan et al. [34] published the
different strains of SARS coronavirus and evaluated the survi-
val of the coronavirus on different surfaces. Results indicated
that survival time of coronavirus with 105 viral titre was 96 h
on wood and glass, 96 h to 120 h on paper and 120 days on
metal. A previous study by Lai et al. [35] has shown that in a
disposable gown under varying inoculum values, coronavirus
was found to be alive up to 48 h in 106 viral titre which dimin-
ished to 24 h in 105 and to 1 h in 104 inoculum. Furthermore,
the viability of SARS coronavirus on plastic surfaces has


























In terms of human endemic coronavirus, a previous study
by Sizun et al. [37] demonstrated that under 5 × 103 viral titre
aluminium surfaces allowed coronavirus to stay alive for 2–
8 h while on latex surgical gloves it was up to 8 h. On the
other hand,Warnes et al. [38] reported a comprehensive analy-
sis (103 infectious titre) about how different materials allow
coronavirus to stay infectious on them. Results indicated that
steel, stainless steel, glass, silicone rubber, PVC, ceramic and
teflon all allowed coronavirus to stay active for 5 days.
Previous work published by van Doremalen et al. [39]
also revealed the viability characteristics of the MERS corona-
virus on surfaces. After testing on steel and plastic under 105
viral titre, results indicated the survival time of the MERS
coronaviruswas 48 hat 20°Cand8–24 hat 30°Conboth surfaces.
There are limited amount of studies published about the
survival characteristics of SARS-CoV-2 on different surfaces.
van Doremalen et al. [17] have recently reported about surface
stability of SARS-CoV-2 and comparison of those character-
istics with SARS-CoV. At 21 to 23°C degrees of ambient
temperature with 105.25 viral titre, steel, air, cardboard and
copper were tested, and results indicated that the SARS-
CoV-2 was able to survive 3 h in air, 4 h on copper, 24 h on
cardboard, 48 h on steel and more than 72 h on plastic. In
addition, Chin et al. [40] reported that persistence of the
SARS-CoV-2 was 96 h on surgical masks and 24 h on cloth
under 107.8 viral titre at 22°C. In figure 4, various surfaces
and survival of different types of coronaviruses under differ-
ent conditions is collated by the authors’ of this review.5. SARS-CoV-2 adsorption mechanism on
different inanimate surfaces
It has recently been found that surface contamination is very
important in terms of transmission of SARS-CoV-2 [41]. Con-
tinuous recontamination with contaminated environmentalsurfaces transfers the infectious virus between humans. Evalu-
ation of the adhesion mechanisms of SARS-CoV-2 on different
inanimate surfaces is crucial for preventing deposition and
designing removal methods. The physico-chemical adherence
and the persistence of SARS-CoV-2 differ with the character-
istics of the inanimate surfaces and the virus outer surface
proteins, as well as on the surrounding environmental con-
ditions, such as air temperature, relative humidity (RH) and
sunlight [42–44].
The adhesion mechanism of SARS-CoV-2 on environ-
mental surfaces has yet to be adequately delineated, but it
has been predicted that it is primarily driven by electrostatic
attractions (e.g. pH, isoelectric point (pI) and ionic strength),
then hydrophobic effects, and minorly non-covalent bonds
(e.g. van der Waals forces) which could all govern the
binding of the S protein to solid surfaces [45].
Since the surface charge of viruses differs with the vary-
ing pH, disruption of electrostatic interactions between
viruses and inanimate surfaces usually involves altering the
pH, pI and ionic strength to manipulate the persistence of
the virus [46,47]. The virus is exceptionally stable over a
wide pH range (3–10) while showing low stability at pH
values (3–5) compared to alkaline pHs (9–12) [48]. The pI
of SARS-CoV-2 has not been defined to understand the
adhesion mechanism of the virus to inanimate surfaces, but
it is assumed that they are largely affected by the isoelectric
properties of the surface glycoproteins (M and N proteins).
Moreover, reduction in the ionic strength of the surrounding
medium between viruses and inanimate surface results in
increased electrostatic interactions and reduce the surface
aggregation of adhered viruses [49]. Van der Waals forces
also play a minor role in the physical adsorption in the
short distance between the virus and inanimate surfaces [50].
The E protein is a highly hydrophobic lipid layer of
SARS-CoV-2 shielding thewhole virus and altering the hydro-
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to surfaces while inactivating this protein [51]. With hydro-
phobic effects, adhesion can be minimized in the interfacial
area between water and apolar surfaces on the viruses,
thereby reducing the binding by decreasing the apolarity of
the virus [52].
Compared to indoor conditions (20–24°C, 40–50% RH),
the stability of SARS-CoV-2 drastically reduces (greater
than 3 log10) at a temperature above 38°C and RH levels
higher than 95% and it causes weaker adhesion for survivor
viruses to solid inanimate surfaces [48]. Additionally, natural
sunlight (low level of UV irradiance 250–280 nm) can be used
on the inactivation of the virus on surfaces with an almost
1000-fold reduction in viral infectivity [53].
Survival of the virus on non-porous material surfaces (e.g.
stainless steel, plastic, latex and glass) was found to be higher
than those on porous material surfaces (e.g. paper and cotton).
It has been found that these porous surfaces can capture
viruses in their matrix and also dehumidifies viruses while
accelerating the destruction process of envelopes and thus
making the virus less infectious [54]. Also, topographic irregu-
larities, texture and roughness of an inanimate surface play arole on virus deposition [55]. Decreased roughness of a surface
and creation of a micro-/nano-multiscale textured surface can
reduce the contact surface area available for virus adhesion
and decrease surface stability for SARS-CoV-2 [56].
The findings on SARS-CoV-2 survival on different
inanimate surfaces are still not sufficient to describe the mech-
anism by which this virus adheres to inanimate surfaces and
further epidemiological research is needed on this topic.6. Inactivation and removal of the coronaviruses
6.1. Surface disinfectant agents
Inactivation and removal of the coronaviruses from surfaces
is an important topic to prevent the spread of the virus and
it requires the incorporation of different chemicals depending
on the type of the surface. Since the physical contact between
inanimate surfaces and hands are frequently occurring
during a regular day, cleaning agents are being investigated
for their antiviral effects. In order to deactivate coronaviruses,




















































































aluminium (5 × 103)
Figure 4. Persistence and viability of different coronavirus strains with different viral titres on most commonly used surface material types (human-CoV: human
endemic coronavirus, MERS-CoV: Middle East respiratory syndrome, SARS-CoV: severe acute respiratory syndrome, SARS-CoV-2: COVID-19). (Data obtained from Duan





suspension tests in which the virus meets the disinfectant in a
suspension has been widely adopted along with the carrier
tests where the virus and disinfectant come together on a
certain surface.
During suspension tests, each chemical was diluted by
volume before the application. Ethanol was frequently used
in increasing concentrations such as 78%, 80%, 85% and
95% with 30 s of exposure time on different coronavirus
types. Reduction of the viral infectivity was reported between
4.3 to 5.5 log10 [57–59]. In the same study reported by Rabe-
nau et al. [57] formaldehyde was also used in 0.7% and 1%
ratios under 2 min of exposure and viral infectivity reduction
was at least 3 log10. Just like ethanol, povidone iodine was
also investigated under different concentrations as well as
against different types of coronaviruses from the beta
family. Results indicated that the usage of povidone iodine
in various ratios ranging from 0.23% to 7.5% under a desig-
nated exposure time of 15 s ended up with 4.4 to 5 log10
reduction in viral titre [60,61]. On the other hand, 2-propanol
is another cleaning agent showing promising results. Results
of testing against different types of coronaviruses indicated
that the 70%, 75% and 100% ratios of 2-propanol resulted in
3.3 to 4.0 log10 viral infectivity reduction under 30 s of
exposure [57,58]. It was also reported that 0.5% hydrogen
peroxide with 1 min of exposure time reached the same
viral infection reduction ratio observed in 0.5% glutardialde-
hyde with 2 min of exposure time, having resulted in at least
4 log10 decrease of the viral infectivity in both cases [57,62].
There are other cleaning agents proven to be ineffective
against coronaviruses. Even though the exposure time was
extended to 10 min, 0.2% benzalkonium chloride reportedno reduction of viral infectivity [63]. Moreover, incorporation
of two different cleaning agents was also tested in order to
reduce the viral infectivity of the coronaviruses. Using a
blend of 45% 2-propanol and 30% 1-propanol, viral infection
reduction was found to be at least 4.3 log10 under 30 s of
exposure, showing a slight increase compared to using 2-pro-
panol only [59].
Figure 5 demonstrates the minimum viral infectivity
reduction each disinfectant can provide under different con-
centrations against different types of coronaviruses with the
given exposure time. According to European standards effi-
ciency criteria, in order to be qualified as an antiseptic and
provide antiviral features, reduction of the viral infectivity
must be at least 4 log10 [64]. Therefore, according to suspen-
sion test results, ethanol, glutardialdehyde and povidone
iodine qualify as proper cleaning agents in order to deactivate
the coronavirus on various surfaces since they were able to
meet the 4 log10 threshold and go beyond that value. It is
also noteworthy that 70% ethanol is also the recommendation
of the WHO [65]. In parallel with the findings, the rest of the
materials can also provide the same level of reduction in
terms of viral infectivity with some of the ratios tested
except benzalkonium chloride and formaldehyde, since both
of these stayed well below the given threshold.
Regardless of the suspension tests, the carrier test of the
different cleaning agents was introduced by Sattar et al. [66].
Under exactly 1 min of exposure time on a stainless-steel sur-
face at room temperature (22–24°C), 70% ethanol, 2%
glutaraldehyde, 0.01, 0.1 and 0.5% sodium hypochlorite and
0.04% benzalkonium chloride diluted by volume were indivi-
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Figure 5. Minimum reduction of viral infectivity values obtained in suspension tests using various disinfectants in different concentrations against different cor-
onaviruses (human-CoV: human endemic coronavirus, MERS-CoV: Middle East respiratory syndrome, SARS-CoV: severe acute respiratory syndrome, SARS-CoV-2:





viral infectivity was assessed according to a selected threshold
of 3 log10 viral infectivity reduction. The main expectation of
viral infectivity reduction on hard objects was reported to be
2 to 4 log10 [67]. As can be seen in figure 6, results indicated
that the ethanol, sodium hypochlorite in 0.1% and 0.5%
ratios, and glutaraldehyde falls above the 3 log10 threshold
and can be considered as effective and promising cleaning
agents for coronaviruses. On the other hand, viral infectivity
reductions of the benzalkonium chloride and 0.01% sodium
hypochlorite were observed to be under the selected threshold
and falls slightly behind the other disinfectants in terms of
viral infection reduction ability [66].
Even though these disinfectant solutions would sound
promising for inanimate surfaces, our hands are more deli-
cate and constant usage of chemicals such as alcohol will
also damage the lipid structure of the skin and compromise
the integrity of it, allowing it to be more exposed and vulner-
able to the microbes. Therefore, usage of the surfactants such
as soap in order to remove coronavirus from hands can be
more realistic, cost effective and beneficial.6.2. Antiviral nanoparticles
A range of nanotechnological concepts, including the use of
silver nanoparticles, have shown to exhibit antiviral activity
against a broad range of viruses with similar mechanisms
of action to antiviral drugs and their performance against
microbial cells [68,69]. As schematically illustrated in figure 7,
it has been found that some nanomaterials can induce anti-
viral activity through the production of ions, generation of
reactive oxygen species (ROS), photothermal and photocata-
lytic effects, and the interaction with viral glycoproteins to
inhibit their binding and penetration [69]. Some of thenanoparticles are known to release ions in suspension and
certain ions have shown antiviral activity against corona-
virus. Metal ions can interact with essential viral enzymes
but other undefined mechanisms also prevail [70–72]. For
example, Zn2+ ions were able to inhibit SARS-CoV replication
through the inhibition of RNA-dependent RNA polymerase
elongation [71]. Similarly, Warnes et al. [38] reported that
copper surfaces were able to destroy the envelope and surface
spikes of human coronavirus 229E, resulting in altered mor-
phology, and therefore expose viral genome which was also
destroyed. Ions produced by the copper surface was respon-
sible for the inactivation of the coronavirus, while the
generation of ROS on the copper surface enhanced the anti-
viral activity. Although bulk material was tested in this
investigation, studies have shown that the release of ions
from metals is proportional to the surface area, and the
exposure of nanoparticles can increase ROS generation.
Thus, copper nanoparticles may exhibit increased antiviral
activity compared to bulk copper [72,73] and some masks
are doped with copper nanoparticles and use this property
already.
While the interaction with coronavirus glycoproteins has
not been reported, the antiviral activity of metal nanoparticles
against other viruses has led to hypothetical theories. Since
gold, silver and silver–copper nanoparticles have a proven
ability to bind to HIV glycoprotein and inactivate the viral
binding and penetration into host cells, it is worth further
exploring for similar mechanisms against coronavirus
[74–77]. Additionally, it is also worth mentioning the potential
of photothermal and photo-catalytic properties of metallic
nanoparticles to disinfect surfaces. It has been reported that
coronaviruses can be inactivated by heat with the temperature



































Figure 6. Comparison of results of the carrier tests in terms of selected threshold 3 log10 using different disinfectants against human-COV on a stainless-steel surface



















can reduce coronavirus by at least 4 log10, while 1 min at 80°C
has the same reduction rate [78]. Currently, photothermal
therapy is used to inactivate cancer cells and has also shown
to inactive virus cells [79]. Although it has not been tested
against coronaviruses, this approach is possible with other
viruses. As an example, murine leukaemia virus has been
successfully inactivated using gold nanorods excited by
805 nm laser [80]. In parallel, photocatalytic effect occurs
when ROS is produced from the excitement caused by UV
light exposure [79]. Nakano et al. [81] have reported influenza
virus inactivation through the photocatalytic activity of
titanium dioxide nanoparticles. As discussed above, the
generation of ROS can induce antiviral activity towards
coronavirus, therefore nanoparticles with photo-catalytic
properties is another possible approach towards inactivation
of coronaviruses.
The use of ‘new’ materials like graphene and its deriva-
tives in combating coronavirus is yet to be fully
investigated. However, these materials can be very effective
against viruses since they display certain antiviral mechan-
isms such as production of ROS, having negative charge,
showing physio-chemical interactions with viruses, competi-
tive inhibition mechanism and inactivating enveloped RNAviruses [82–84]. Additionally, action mechanisms of graphene
and valuable features of its derivatives have already inspired
researchers for adopting these interactions to propose new
studies against SARS-CoV-2 in different application areas
and roles [85].6.3. Role of antiviral drugs
Another concept that can inactivate coronaviruses is antiviral
drugs. Even though it is not directly related to inanimate sur-
faces, understanding the virus inactivation mechanism of
antiviral drugs and their relationship to proteins of the SARS-
CoV-2 might also be beneficial for further understanding of
possible coating materials which can be used on inanimate
surfaces in terms of replicating the same effect. Despite years
of intensive research on antiviral drugs against human corona-
virus, there is currently no approved or effective treatment for
SARS-CoV, SARS-CoV-2 or MERS-CoV. However, there are
ongoing investigations on suggested FDA approved drugs or
repurposed drugs as antiviral candidates [86,87].
Repurposed drugs have shown successful results that
target the viruses using a variety of predicted mechanisms,
although they are not currently recommended for use outside
Table 1. Examples of repurposed drugs that have shown positive activity against coronavirus in terms of blocking cell entrance by inhibiting the virus and cell
interactions.
drug dosage target virus
approved
clinical status main result
predicted antiviral
mechanism of action reference
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ivermectin 5 µM/48 h SARS-CoV-2 anti-parasitic
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clinical trials [86,88,89]. As a whole, antiviral drugs exhibit
different mechanisms of action such as binding and fusion
inhibitors, enzyme and channel blockers as well as poly-
merase, kinase, protease and cyclophilin inhibitors; each
targeting particular stages of the viral cycle. The interaction
of the antiviral drugs and S proteins of the coronaviruses
might be the most beneficial to focus on since it can give per-
spective to understand how other materials might interact
with those spike proteins. As the viral cells attach to host
cells through interactions between surface proteins and recep-
tors, they can subsequently penetrate into host cells [90].
Certain drugs can target and inhibit the binding of viral cells
to host cells or inhibit fusion, for example inhibiting viral sur-
face proteins [91]. Examples of repurposed drugs that have
interactions with spike and surface proteins are shown in
table 1 and a common mechanism of actions include blocked
entry (which targets the attachment and penetration of the
virus into the host) [88].6.4. Nanotechnological approaches against COVID-19
Nanotechnology is a highly complex but promising concept
that has already been widely adapted against COVID-19
since the SARS-CoV-2 virus and nanotechnological tools
operate on a similar size scale [97]. Understanding, altering
and controlling those interactions can help researchers to
develop rapid and more accurate virus detection implemen-
tations and better control tools as well as more effective
PPE [98–100].Along with the antiviral properties of the nano-sized
particles discussed in the previous sections, nanotechnology
can also be integrated into this ongoing COVID-19 battle in
terms of detection of the disease. The currently employed
main diagnosis method is based on the nucleic acid testing
mechanism namely reverse transcription-polymerase chain
reaction (RT-PCR). However, this method comes with certain
limitations in terms of real-life applicability since the RT-
PCR test may be incapable of revealing patients that are
not showing symptoms. Additionally, not every healthcare
centre or hospital, especially smaller organizations without
enough facilities, can handle the massive workload caused
by increased demand due to insufficient PCR testing capabili-
ties and, finally, number of kits and reagents available are
insufficient to meet spiking demand in general [101]. With
the aim of compensating for these problems, a former biosen-
sor-based pathogenic detection system has been incorporated
with the current reverse transcription (RT) method by Zhu
et al. [102], resulting in a one-step, effective and low-cost diag-
nosis tool for SARS-CoV-2 suitable for laboratories and
healthcare centres that are resource limited. As reported by
Chen et al. [103], a novel way of virus detection can also be
achieved by using biomimetic nanoparticles interacting with
viruses for enhancing their exposure to certain detection
tools. Therefore, it can be said that nanotechnological
approaches hold remarkable potential in terms of improving
testing and detection capabilities. Point of care testing concept
was also built on strong fundamentals owing to nanotechnol-




10studies showing that gold nanoparticles can help develop new
and enhanced detection methods that can be suitable for point
of care applications without needing a laboratory to send
samples to and fro can be extremely beneficial in certain scen-
arios. Furthermore, nanotechnology can also create a difference
when it comes to controlling the spread of the disease. Medhi
et al. [104] demonstrated how nanotechnology-based strategies
can be beneficial for blocking cell attachment and controlling
the spread of the virus. Not only limited to that, a recent
study proposed usage of nanoparticles to create decoy targets
for SARS-CoV-2 to attach, absorbing viruses and hindering
their chance to contact cells to reduce the rate of developing
an infection [105]. Moreover, previous studies reveal how
nanotechnological approaches can reach out further by pio-
neering the creation of improved PPE and nano-sized drug
delivery systems to overcome COVID-19 [106,107].
Among mentioned prevention methods which are the
first line of defence for tackling the overwhelming course of
the pandemic, the real challenge lies in vaccine development
studies. The importance of nanotechnological approaches has
already been suggested in terms of developing a safe and
effective vaccine against COVID-19 [108–110].987. Conclusion and future perspectives
It is a fact that the advent of the pandemic has changed the
tide of our lives and as human beings we are all obliged to
understand and adapt new aspects in order to protect our-
selves and society. SARS-CoV-2, the coronavirus strain
which is responsible for current COVID-19 pandemic has
already spread all over the world and keeps transmitting
between individuals, targeting vulnerable people more, as
well as the healthcare industry and worldwide economy.As the world struggles to find a vaccine or an effective
drug in order to overcome this threat as a whole, these
goals are still quite far away from reality as we have so
much to develop with respect to these concepts. Therefore,
this review focuses on viability of the coronaviruses on inan-
imate surfaces since they are crucial and frequent vectors of
transmission as well as this knowledge sheds light on the dis-
infectant chemicals reported in previous studies in order to
inhibit the infection ability of the coronaviruses. This can be
done by analysing the morphology of the coronavirus,
virus protein to cell enzyme interactions while considering
the lessons learnt from the past such as the SARS epidemic
and the MERS outbreak by comparing related coronavirus
strains causing those diseases. Not only limited to that, mech-
anisms of virus response against surfaces, nanoparticles and
antiviral drugs were also investigated from previously pub-
lished articles. However, further epidemiological research is
crucial and urgently needed on this topic to understand the
behaviour of SARS-CoV-2 to come up with stronger protocols
to fight against COVID-19.
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